Skip to main
ASTH

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health is expected to continue its positive trajectory with the end of the ACO REACH program and the adoption of the new LEAD model, as demonstrated by the 8.4% savings and 75% quality score of its ACOs in the program. Moreover, Astrana's payer-agnostic platform and partnerships with a wide range of health plans, along with its focus on preventive care for seniors, position it well in the industry alongside other successful companies such as Privia, Oak Street, and Agilon Health. With a strong balance sheet and a proven track record in the value-based care space, Astrana Health's stock is expected to continue its upward trend, making it a promising investment opportunity.

Bears say

Astrana Health is well-positioned for long-term growth and success in the value-based care space, with its strong track record in delivering high-quality care and generating cost-savings. Its ACO REACH programs are performing well, with a savings rate above the industry average. The acquisition of Prospect Medical and its Knox Keene License positions Astrana to capture more capitated premiums in the future. However, the company's heavy reliance on Medicare and Medicaid revenue and potential risks from changes in healthcare legislation and increased competition in the market should be closely monitored. The stock is currently undervalued compared to its peers, and its strong cash flow generation in Q1 and Q2 is expected to support its growth.

ASTH has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 7 analysts, ASTH has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.